Belantamab mafodotin-blmf (Blenrep), lenalidomide (Revlimid), and dexamethasone yielded high rates of complete response (CR) and low rates of ocular toxicity in intermediate-fit or frail patients with newly diagnosed multiple myeloma, according to lo... [9068 chars].. reed more
